Source: Theta Gold Mines/Twitter
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Theta Gold Mines (TGM) enters an agreement with 2Invest AG, giving it the option to extend its maturity date for the outstanding $6 million secured bond
  • The company said the bond will be extended a further 12 months
  • All other existing terms and conditions of the secured bond remain unchanged
  • TGM shares are in the grey and trading at 12 cents

Theta Gold Mines (TGM) has entered into an agreement to extend its maturity date for the outstanding $6 million secured bond with 2Invest AG.

Previously, the maturity date and repayment of the bond was January 23, which may be extended a further 12 months to January 23, 2024, at the discretion of the board.

All other existing terms and conditions of the secured bond remain unchanged.

Under the agreement, Theta will issue 15 million unlisted Series C Options to 2Invest AG at a price of 17 cents per share, with an expiry date on or before January 16, 2024.

“We are very pleased to have 2Invest’s ongoing support and would certainly welcome them to increase their equity holding in the company via exercising the various call options held while the company’s progressing towards funding, construction and production,” Chairman Bill Guy said.

On the market, TGM shares are in the grey and trading at 12 cents at 2:01 pm AEST.

TGM by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX steams uphill but still on track to recovery

The ASX200 closed .4 of a per cent up with IT and Health Care the locomotives…
The Market Online Video

Market Update: ASX edges up with a healthier disposition

The ASX200 is trading up around half a per cent with Health Care and Real Estate…
Magnetite

Fe grades above 71% make Cyclone Metals bullish about Iron Bear pilot plant

Cyclone Metals, an iron ore developer which has built its business progressing Canadian magnetite play Iron…

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…